Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • Telephone

      • +91 22-69790010 from 9 AM - 5:30 PM IST

      • Contact
      • Contact

        +91 22-69790010
        from 9 AM - 5:30 PM IST

    Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • 2 News in Focus
    • 5 Business & Money
    • 5 Science & Tech
    • 5 Lifestyle & Health
    • 1 Policy & Public Interest
    • 1 People & Culture
    • Request More Information
    • Journalists
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • Request More Information
    • Journalists
    • General Inquiries
    • Worldwide Offices
    • Request More Information
    • Journalists
    Close submenu (News in Focus) News in Focus
    • Browse News Releases
    • Multimedia Gallery
    Close submenu (Business & Money) Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    Close submenu (Science & Tech) Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    Close submenu (Lifestyle & Health) Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    Close submenu (Policy & Public Interest) Policy & Public Interest
    • Policy & Public Interest
    Close submenu (People & Culture) People & Culture
    • People & Culture

    Dr. Jekyll and Mr. Hyde: Two sides of the Immune system

    Zydus Hospital Logo

    News provided by

    Zydus Hospitals and Healthcare Research Private Limited

    19 Nov, 2026, 10:00 IST

    Share this article

    Share this article


    How Zydus hospital, Ahmedabad is implementing novel targeted medicines to match the changing treatment landscape of allergies and autoimmune diseases, often with little or no steroid

    AHMEDABAD, India, Nov. 19, 2026 /PRNewswire/ -- Like Dr. Jekyll and Mr. Hyde, the immune system has two sides: a protector and, when things go wrong, a threat. The immune system defends the body against infections by attacking germs and abnormal cells without harming the body's own healthy cells, an ability known as immune tolerance. When tolerance breaks down, the immune system can react to harmless substances, which causes an allergy, or attack the body's own tissues, which causes an autoimmune disease. For many years, treatment depended largely on steroids and other medicines that suppress the entire immune system which could cause side effects with long-term use, including weight gain, weakened bones, raised blood sugar and a higher risk of infections. Newer therapies, including biologics (laboratory-made antibodies), allow doctors to act on specific parts of the immune response that drives the disease, and some of these don't even increase the risk of infections and reduce the overall collateral damage that was caused by older therapies.

    Continue Reading
    Illustrative image of an allergen
    Illustrative image of an allergen

    Zydus Hospitals, Ahmedabad, offers a complete diagnostic work-up of these conditions, supported by a laboratory equipped for comprehensive allergy profiling. Dr. Kunal Chandwar, Allergist-Immunologist and Rheumatologist in Ahmedabad, has been trained across multiple countries and specialises in allergy, clinical immunology and rheumatology, and in matching each patient with the targeted therapy that suits the pathway driving their disease. When the faulty immune pathway is correctly identified, the right targeted treatment can be chosen, and in many patients steroids can be avoided or used sparingly.

    To show how serious an allergy can be, Dr. Chandwar recounts a recent case of a 9-year-old boy with a severe allergy to cow's milk, who went into anaphylactic shock (a sudden, life-threatening allergic reaction that affects breathing and blood pressure) after eating ghee. Ghee contains only traces of milk protein, so a reaction to it points to extreme sensitivity. In many allergies, the molecule at fault is immunoglobulin E (IgE), an antibody that wrongly marks an otherwise harmless food as a 'threat'. Treatment depends on the condition and its severity. The first step is to identify and avoid the trigger. The boy had lived with allergy for 9 years before his family consulted Dr. Chandwar, an immunologist in Ahmedabad, who started him on omalizumab, a targeted biologic and the only one approved by the US FDA for IgE-mediated food allergy. Omalizumab binds to IgE in the blood and stops it from setting off mast cells (the cells that release histamine), and reduces the chances of an allergic reaction. "Milk immunotherapy is now possible. We used the 'milk ladder approach' in which we gradually reintroduced the milk allergen into the patient's diet. We start with its least allergy-inducing form and slowly progress to the most allergy-inducing form. The boy is doing well and after 2 years on this therapy, he can now tolerate small amounts of biscuits and cakes," says Dr. Chandwar. The therapy does not cure the allergy and he must continue to avoid milk, but it raises the amount of milk protein needed to trigger a reaction, which lowers the risk from accidental exposure. Such treatment, including the milk ladder, should only be attempted under specialist supervision and never at home on one's own.

    Speaking about his experience in rheumatology, he explains that the skin and joints are common targets of autoimmune diseases. Psoriasis is a long-term, non-contagious condition in which skin cells multiply too quickly and build up as thick, red, scaly patches, and some patients also develop joint inflammation, called psoriatic arthritis. A 27-year-old man consulted Dr. Chandwar after a year and a half of psoriasis affecting about 90 per cent of his skin, together with psoriatic arthritis. He was prescribed ixekizumab, a biologic that blocks interleukin-17 (IL-17), one of the chemical signals that drive the disease. More than ten biologics are now approved for psoriasis, and each acts on different inflammatory pathways. After a month and a half, his condition improved by more than 80 % without the need for steroids. Upon follow-up, no new patches had appeared, and his recovery was smoother and faster. This shows how identifying the pathway that drives a disease leads to the right targeted drug.

    Some autoimmune diseases also affect internal organs. In lupus (systemic lupus erythematosus, or SLE), the immune system attacks the body's own tissues, damaging the skin, joints, blood vessels and kidneys. Common symptoms are joint pain and swelling, unexplained fever and a red rash across the nose and cheeks, often called a butterfly rash because of its shape. In as many as half of adult patients, the disease affects the kidneys, a complication known as lupus nephritis. If the kidneys fail, dialysis or a kidney transplant becomes necessary. One such patient, an 18-year-old woman, had been diagnosed with lupus nephritis before she consulted Dr. Chandwar. Her condition had deteriorated as she developed lupus myocarditis (inflammation of the heart muscle), in which her heart's pumping function (ejection fraction) dropped to 10%, and she needed dialysis for six months to support her failing kidneys, even while being treated with rituximab. This biologic removes B cells, the white blood cells responsible for producing antibodies, and is used in severe lupus, usually when standard medicines have not been sufficient. With rituximab, her heart and kidney function gradually improved, returning to normal.

    ANCA-associated vasculitis, another condition he treats, is a rarer autoimmune disease and one that can become dangerous quickly. Vasculitis means inflammation of the blood vessels. In this form, the immune system produces abnormal antibodies called ANCA (anti-neutrophil cytoplasmic antibodies). These abnormal antibodies attach to neutrophils (a type of white blood cell that normally fights infection), and make them attack the walls of small blood vessels. The vessels become inflamed and may bleed, and the organs they supply, commonly the skin, lungs and kidneys, can be damaged. A woman who developed the disease at just 18 had severe vasculitis of the skin and bleeding in the lungs, both of which are medical emergencies. She was treated with rituximab for 6 months and recovered gradually. Two biologics are approved for this group of diseases: rituximab (for granulomatosis with polyangiitis and microscopic polyangiitis) and mepolizumab (for its eosinophilic form).

    Most of these conditions cannot yet be cured, but they can be controlled, and with regular treatment and follow-up, many patients can experience a better quality of life. Biologics are now increasingly chosen based on the immune pathway driving a patient's disease. This is why an accurate diagnosis matters: similar symptoms can arise from different pathways, and a medicine that works well for one may not help another. Biologics such as mepolizumab and benralizumab, which reduce eosinophils (white blood cells that drive allergic inflammation), are proving useful in managing conditions such as chronic rhinosinusitis with nasal polyps and severe asthma (seven US FDA-approved biologics are now available for severe asthma), and dupilumab, which blocks the IL-4 and IL-13 signals, has shown promising results in patients with atopic dermatitis (a chronic, itchy form of eczema), for which four biologics are now approved. CAR T-cell therapy, in which a patient's own immune cells are modified in the laboratory to remove the B cells that drive disease. It is emerging as one of the newest treatment approaches with promising outcomes for autoimmune diseases.

    In autoimmune and allergy disorders, early detection helps in better management of the disease. Persistent joint pain, swelling or morning stiffness, recurring allergic problems, severe itching, can all be reasons to consult an allergy specialist in Ahmedabad, a clinical immunologist or rheumatologist. Biologics are powerful medicines that need a precise diagnosis and should never be started without specialist supervision. Zydus Hospital, Ahmedabad offers a combination of diagnostic and clinical expertise across the spectrum of allergic and immunological disorders.

    To know more, visit https://zydushospitals.com 

    Modal title

    Also from this source

    /C O R R E C T I O N -- Zydus Hospitals and Healthcare Research Private Limited/

    /C O R R E C T I O N -- Zydus Hospitals and Healthcare Research Private Limited/

    More than three billion people, over 40 per cent of the world's population, are affected by neurological conditions, according to the World Health...

    Zydus Hospitals, Ahmedabad, Takes Post-Weight-Loss Transformation Beyond the Scale

    Zydus Hospitals, Ahmedabad, Takes Post-Weight-Loss Transformation Beyond the Scale

    India is in the middle of a significant obesity crisis, and global estimates place the country third in the world for the number of adults living...

    More Releases From This Source

    Explore

    Medical Pharmaceuticals

    Medical Pharmaceuticals

    Pharmaceuticals

    Pharmaceuticals

    Health Care & Hospitals

    Health Care & Hospitals

    Clinical Trials & Medical Discoveries

    Clinical Trials & Medical Discoveries

    News Releases in Similar Topics

    Contact PR Newswire

    • +91 22-69790010

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +91 (0) 22 6169 6000
    from 9 AM - 5:30 PM IST
    • Terms of Use
    • Privacy Policy
    • GDPR
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.